Surgical treatment of medication-related osteonecrosis of the jaw in patients with autoimmune diseases

Abstract

This retrospective, single-center study compares the factors influencing the surgical outcomes of medication-related osteonecrosis of the jaw (MRONJ) in patients with and without autoimmune diseases (AIDs). The total surgical success rate was 92% during the mean 2-year follow-up period, and treatment failure was observed in 8% of all patients without AID and 12% of patients with AIDs. Bisphosphonate duration and administration route (intravenous) were found to be risk factors of MRONJ. A careful treatment plan should be developed with a multidisciplinary team including a rheumatologist and a maxillofacial surgeon to avoid the use of drugs that may adversely affect treatment results when MRONJ occurs in patients with AIDs.